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Abstract
The development of a rapid, high-throughput and cost-effective HIV-1 drug resistance (HIV-
DR) testing system is a challenge for areas consisting different HIV-1 strains. In this study,
we established a broadly reactive multiplex assay that could simultaneously detect major
drug resistance mutations at 8 loci, which are associated with resistance to commonly used
nucleoside reverse transcriptase inhibitors (NRTIs) and Non-nucleoside reverse transcrip-
tase inhibitors (NNRTIs), in specimens of HIV-1 CRF01_AE, CRF07_BC and subtype B,
the three major circulating strains in China, using the matrix-assisted laser desorption ioni-
zation-time of flight mass spectrometry (MALDI-TOF MS) provided by SequenomMassAR-
RAY1 system. To establish the assay, pol gene fragments were prepared from the plasma
viral RNA of 159 patients by nested PCR and the presence of wild type and mutant alleles
at the 8 loci were analyzed by MALDI-TOF MS. In terms of loci, the detection rate of the
alleles was greater than 97% for M41L, K65R, M184V and G190A, 91.2% for K101E/Q/P,
91.2% for T215F/Y, 89.9% for K103N/S and 80.5% for L210W. In terms of individuals, 80%
of the alleles were detected in 95.4% CRF01_AE patients, 100% CRF07_BC patients and
83.3% subtype B patients. Importantly, the MALDI-TOF MS results were concordant to the
drug resistance profiles of patients obtained from conventional sequencing analysis after
excluded the failed detections. Using plasmid templates, the assay was estimated to be
sensitive to detect drug resistant variants at level about 20% of the circulating viral popula-
tion. The capability of this assay to detect mixed viral populations was further verified by two
different patient specimens. In conclusion, this study evaluated the use of Sequenom
PLOSONE | DOI:10.1371/journal.pone.0153641 April 19, 2016 1 / 15
a11111
OPEN ACCESS
Citation: Cheung K-W, Peng Q, He L, Cai K, Jiang
Q, Zhou B, et al. (2016) Rapid and Simultaneous
Detection of Major Drug Resistance Mutations in
Reverse Transcriptase Gene for HIV-1 CRF01_AE,
CRF07_BC and Subtype B in China Using
Sequenom MassARRAY1 System. PLoS ONE 11
(4): e0153641. doi:10.1371/journal.pone.0153641
Editor: Kok Keng Tee, University of Malaya,
MALAYSIA
Received: November 29, 2015
Accepted: April 1, 2016
Published: April 19, 2016
Copyright: © 2016 Cheung et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information files.
Funding: This work was supported by Hong Kong
AIDS Trust Fund (MSS183R) to ZC (www.atf.gov.hk)
and Science and Technology key projects
(201001010) to HW. The authors thank the University
Development Fund (HKU-UDF) and Li Ka Shing
Faculty of Medicine Matching Fund (www.hku.hk) for
financial supports to AIDS Institute. The authors also
thank for the support of Hong Kong AIDS Trust Fund
(MSS227R) to ZC and Shenzhen San-Ming Program
MassARRAY1 system for high-throughput detection of HIV-DR mutations towards the
commonly used reverse transcriptase inhibitors in China.
Introduction
Over the past 3 decades, HIV-1/AIDS has become one of the world’s leading infectious diseases
and has already caused over 30 million deaths throughout the world. The development of anti-
retroviral drugs and implementation of highly active antiretroviral therapy (HAART) have
remarkably reduced the morbidity and mortality caused by HIV-1 infection [1]. Despite the
dramatic reduction of plasma HIV-1 level in patients on HAART, the virus is not eradicated
and a lifelong treatment is required. Apart from the side effects, drug resistant HIV-1 evolved
under the selective pressure imposed by antiretroviral drugs after long-term treatment proba-
bly leads to clinical manifestation. To date, drug resistant HIV-1 has been readily found and is
transmitting in many countries where antiretroviral treatment is provided [2,3].
Based on the international guidelines for antiretroviral treatment, drug resistance test is rec-
ommended before HAART and in patients of confirmed virologic failure [4]. Current drug
resistance assays can be divided into genotypic assay and phenotypic assay. Genotypic assay
bases on the determination of specific point mutations on the nucleotide sequences of the
patient’s virus whereas phenotypic assay bases on measuring the replication of virus isolates
from patients in the presence or absence of drugs. The major difference between these two
methods is that genotypic assay can generate resistance profiles in a faster, more informative
and cost effective way.
Conventional sequencing based assays including ViroSeq [5] and TruGene [6] as well as
many in-house assays [7,8] are widely adopted for genotypic drug resistance testing in clinical
settings. However, these assays are often not sensitive enough and are labor-intensive for the
detection of the low abundance mutations. SequenomMassARRAY1 system is a DNA analy-
sis platform which has been widely utilized for high-throughput genotyping studies such as sin-
gle nucleotide polymorphism (SNP) detection [9–12] based on the matrix-assisted laser
desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). In the context of
HIV-1, a change from wild type allele to mutant allele in a virus would result in products with
mass differences from the wild type strain after primer-extension reactions and therefore
enables drug resistance detection by MALDI-TOF MS.
Due to the mounting evidence that antiretroviral therapy is beneficial to HIV-1 prevention
and the increasing emergence and transmission rate of drug resistant HIV-1 [1–3,13], the
demand for rapid, high-throughput and cost-effective drug resistance testing system is signifi-
cantly elevated, especially in areas where limited antiretroviral drug variety supplied. Also,
there are only few multiplex assays that can detect drug resistance mutations for various HIV-1
subtypes simultaneously [14]. In this study, we established a multiplex assay for detecting the
drug resistance mutations at 8 loci (M41L, K65R, K101E/Q/P, K103N/S, M184V, G190A,
L210W and T215F/Y), which are associated with resistance to commonly used nucleoside
reverse transcriptase inhibitors (NRTIs) and Non-nucleoside reverse transcriptase inhibitors
(NNRTIs) based on the automated MassARRAY1 system (Sequenom). The assay was vali-
dated in 159 patients mainly infected with HIV-1 CRF01_AE, CRF07_BC and subtype B, the
three major circulating strains in China [15,16]. This study provided a technical base and eval-
uated the potential use of SequenomMassARRAY1 system for high-throughput detection of
HIV-1 drug resistance (HIV-DR) mutations in China.
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Materials and Methods
Specimens
159 plasma specimens were collected between 2011 and 2013 from HAART experienced or
treatment naïve HIV-1 infected patients at the AIDS clinic of Shenzhen Third people’s Hospi-
tal after written informed consent was obtained from each participant. This study was con-
ducted in compliance with the Declaration of Helsinki and was approved by the ethics review
committee of Shenzhen Third people’s Hospital. The drug resistance profiles of all specimens
were undetermined at the time of collection. The demographic characteristics of the specimens
were summarized in Table 1.
RNA extraction, cDNA synthesis, amplification of first round PCR
products of the nested PCR and viral load determination
5ml peripheral blood from each patient was collected into red-top tubes containing anticoagu-
lant. After centrifugation, 2ml plasma was collected and stored at -80°C. HIV-1 viral RNA was
extracted from plasma with the High Pure Viral RNA kit (Roche) according to manufacturer’s
instruction. cDNA synthesis and the amplification of first round PCR products of the nested
PCR were prepared by PrimeScriptTM one step RT-PCR kit Ver.2.0 (Takara) following the
manufacturer’s instruction. In detail, the reaction mixture (25μl) for cDNA synthesis and first
round PCR contained 5μl extracted viral RNA (4–25μg/ml) and 0.4μM first round PCR prim-
ers. The viral load of each specimen was determined by careHIV-1 RT-PCR Assay (Qiagen)
and analyzed by Lightcycler (Roche) following the manufacturer’s instruction.
Extension primer design and detection of drug resistance mutations in
the pol gene fragment of HIV-1
The drug resistance mutations towards reverse transcriptase inhibitors in the pol gene fragment
were detected by MALDI-TOF MS using Sequenom massARRAY1 system. The extension
primers for detecting the wild type and the drug resistant mutant alleles in the pol gene frag-
ment were designed by MassARRAY1 Assay Design 3.1 software. All the primers were pur-
chased from Tech Dragon Limited and other reagents were purchased from Sequenom unless
otherwise specified.
4 main steps for the detection of HIV-1 variants by MALDI-TOF MS
Nested PCR to amplify the pol gene fragment. The pol gene fragment with size around
1257bp including the protease gene and the first 313 codons of reverse transcriptase gene was
amplified using nested PCR method. The first round PCR was performed with primer pairs
PR/RT F1 (sense: 5’-YYC AgA gCA gAC Cag AgC CAA C -3’) and PR/RT R1 (antisense: 5’-
CYT gCC AAT AST CYR TCC ACC-3’) and the second round PCR was performed with
primer pairs PR/RT F2 (sense: 5’- CTT CCC TCA GAT CAC TCT TTG GC -3’) and PR/RT
R2 (antisense: 5’- GCT CTT GAT AAA TTT GGT ATG TCC ATT G -3’). The first round PCR
products were directly generated from viral RNA using PrimeScriptTM one step RT-PCR kit
Ver.2.0 as mentioned above at thermal cycling conditions: 50°C for 30min, 94°C for 2min, fol-
lowed by 30 cycles of 94°C for 30s, 58°C for 30s, and 72°C for 1.5min, with a last extension step
of 72°C for 7min. The second round PCR was conducted by using PrimeSTAR (Takara) with
thermo cycling conditions: 98°C for 3min, followed by 30 cycles of 98°C for 10s, 60°C for 5s,
and 72°C for 1min, with a last extension step of 72°C for 7min.
Shrimp Alkaline phosphatase (SAP) Treatment. The unincorporated dNTP in the PCR
reaction was neutralized by SAP solution provided in the SpectroCHIP Arrays and Clean resin
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kit according to the manufacturer’s instruction (Sequenom). In brief, 4μl of PCR product was
first aliquoted into 384 wells plate, mixed with 2μl SAP solution followed by incubating in 37°C
for 40 min. The reactions were stopped by inactivation at 85°C for 5 min.
Multiplex primer extension reactions. The 8 selected drug resistance mutations towards
reverse transcriptase inhibitors were analyzed in 6 separate primer-extension reactions (6-plex
in assay 1, 5-plex in assay 2, 4-plex in assay 3, 4-plex in assay 4, 2-plex in assay 5, 1-plex in
assay 6). The sequences and molecular weights of extension primers and extension products
were listed in S1 Fig. The reaction was performed following the manufacturer’s instruction.
Table 1. Demographic characteristics of 159 HIV-1-infected patients.
Characteristic Value
Mean age in years (range) 36.3(2–67)
No. male (%) 130(81.8)
No. female (%) 29(18.2)
Risk factor for HIV infection (% of patients)
Heterosexual 79(49.7)
Homosexual 65(40.9)
Vertical transmission 1(0.6)
Intravenous drug 3(1.9)
Unknown 11(6.9)
WHO clinical stage (%)
I 35(22.0)
II 48(30.2)
III 1(0.6)
VI 63(39.6)
Unknown 12(7.5)
Subtyping (%)
CRF01_AE 109(68.6)
CRF07_BC 26(16.4)
CRF08_BC 2(1.3)
B 12(7.5)
URF_01/BC 3(1.9)
CRF02_AG 1(0.6)
URF_01/C 1(0.6)
Undetermined 5(3.1)
Mean CD4 cell count (No. of cells/μl [range]) a 208(1–1663)
No. of unknown (%) 6(3.8)
Median HIV-1 RNA (log10 copies/ml)(interquartile range)
b 5.7(5.1–6.3)
No. of HIV-1 <500 copies/ml (%) 4(2.5)
History of actual treatment (No. of patients) (%)
No ART 126(79.2)
With NRTI 1(0.6)
With NRTI plus NNRTI 24(15.1)
With NRTI plus PI 1(0.6)
With NRTI plus NNRTI plus PI 7(4.4)
NRTI, nucleoside reverse transcriptase inhibitor: lamivudine, tenofovir, stavudine, zidovudine; NNRTI, non-
nucleoside reverse transcriptase inhibitor: efavirenz, nevirapine; PI, protease inhibitor: ritonavir, lopinavir
a: The CD4 cell count of the 2 years old patient (No. of cells/μl: 1078) is excluded
b: The viral load of the 4 patients with HIV-1 copy number less than 500 copies/ml is not included
doi:10.1371/journal.pone.0153641.t001
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Sample conditioning, Data acquiring and analysis. The extension products obtained
were desalted by adding 16μl double distilled water and 6mg SpectroCLEAN resin before
MALDI-TOF MS analysis. The 384 wells plate containing the samples was centrifuged at 360g
for 5 min before transferring the samples to the SpectroCHIP via the MassARRAYnano dis-
penser. Data from SpectroCHIP was acquired by MassARRAY1 System (Sequenom) and ana-
lyzed by TyperAnalyzer Application, version 4.0 (Sequenom).
TA cloning
Pol gene fragment was amplified using Taq polymerase (Takara) with the first round PCR
products served as template. The amplified PCR product was then cloned into TA cloning vec-
tor (Takara) and transformed into Escherichia coli (E.coli) cells (DH5α) according to the man-
ufacturer’s instruction. Transformed cells were selected on a LB agar plate containing 100μg/
ml ampicillin at 37°C for 16–18 hours. Positive transformants were picked and inoculated into
2ml LB broth containing 100μg/ml ampicillin for plasmid propagation. Successful ligation was
verified by PCR using second round PCR primers for PR/RT region as mentioned and DNA
sequencing.
Plasmid isolation and construction of plasmid containing M184V
mutation
Plasmid was isolated from E.coli (DH5α) using mini-prep DNA purification kit (Qiagen)
according to the manufacturer’s instruction. Purified plasmid was then subjected to site-
directed mutagenesis using the QuikChange II Site-Directed Mutagenesis kit (Agilent technol-
ogies) for the construction of 184V mutant. Successful mutagenesis was verified by PCR ampli-
fication of the pol gene fragment followed by DNA sequencing.
DNA sequencing
All the PCR products were sequenced at Beijing Genomic Institute-Shenzhen (BGI-Shenzhen).
The sequencing primers used were the same as the primer pairs PR/RT F2 and PR/RT R2 as
mentioned above.
Genotypic analysis of HIV-1 drug resistance in patient specimens
Sequence data of the Pol gene fragment of each patient specimen obtained from DNA sequenc-
ing was submitted to Stanford University HIV drug resistance database for generating an anti-
retroviral drug resistance profile [17].
Results
Amplification of the pol gene fragment from HIV-1 CRF01AE,
CRF07_BC and subtype B for drug resistance mutation detection
The vast genetic variation among HIV-1 isolates often increases the difficulties for the develop-
ment of assay platforms for genotypic drug resistance assay, especially the one for multiplex
detection. In order to detect alleles responsible for HIV-DR mutations towards reverse tran-
scriptase inhibitors as well as to increase the efficiency and efficacy of our assay, we adapted the
nested PCR method as described previously [18]. Result in Fig 1 illustrated the nested PCR
method in this study was capable to amplify the pol gene fragment with high specificity from
HIV-1 CRF01_AE, CRF07_BC and subtype B. The primers also worked for the amplification
Detection of HIV-DRMutations in Reverse Transcriptase Gene Using SequenomMassARRAY1 System
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of same region from HIV-1 of other subtypes, such as URF_01/BC. The PCR products were
confirmed to be the desired region by DNA sequencing.
Performance evaluation by using clinical specimens
To evaluate the performance of the MALDI-TOFMS based assay, we analyzed plasma speci-
mens from 159 patients. The demographic characteristics of these patients were summarized
in Table 1. In this study, the performance of the assay was defined in 2 contexts as described
previously [10]: 1) the call rate per allele, which was the percentage of successful call for an
indicated allele among all specimens, and 2) the call rate per sample, which was the percentage
of alleles successfully called in each individual specimen.
Firstly, we considered the call rate per allele. As shown in Table 2, 9 out of 10 alleles except
L210W achieved a call rate greater than 90%. The overall call rate for all alleles in all 159 speci-
mens was 93.8%. More importantly, the call rate per allele for codon 65, 184 and 190, which
were the 3 most common drug resistance mutation sites found among our specimens, were
greater than 97%. Since 2 simultaneous point mutations were required for converting the lysine
(K) into glutamic acid (E), glutamine (Q) or proline (P) in codon 101 and asparagine (N) or
Fig 1. Amplification of pol gene fragment by nested PCR. Viral RNA extracted from plasma specimens of patients was first converted to cDNA and the pol
gene fragment was amplified by nested PCR. Result of gel electrophoresis illustrated the nested PCRmethod was capable to amplify the pol gene fragment
with high specificity from HIV-1 of various strains as indicated.
doi:10.1371/journal.pone.0153641.g001
Table 2. Summary of the call rate per allele.
Allele detected at
each site a
Call rate per
allele (%)
Combined call rate for K101E/Q/
P and K103N/S (%)
M41L [A/c/t]TG 97.5
K65R A[A/g]A 100
K101E/Q/P [A/g/c]AA 91.2 91.2
K101E/Q/P A[A/c]A 98.7
K103N/S A[A/g]A 90.6 89.9
K103N/S AA[A/G/t/c] 91.2
M184V [A/g]TG 97.5
G190A G[G/c]A 99.4
L210W T[T/g]G 80.5
T215F/Y [A/t]CC 91.2
Overall call rate for all
1590 alleles (%)
93.8
a Alleles to be detected are shown in the brackets and the small letters represent the mutant alleles
doi:10.1371/journal.pone.0153641.t002
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serine (S) in codon 103, 2 alleles were required to be called simultaneously in order to give con-
clusive results for K101E/Q/P and K103N/S. According to our result, the 2 pairs of alleles were
called simultaneously in 145 out of 159 specimens for K101E/Q/P (91.2% of the total speci-
mens) and in 143 out of 159 specimens (89.9% of the total specimens) for K103N/S.
The call rate per sample was subsequently evaluated in order to examine the effectiveness
for clinical application. As shown in Fig 2I, 130 out of 159 (81.8%) specimens had a call rate
greater than 90%, 149 out of 159 (93.7%) specimens had a call rate greater than 80%. We fur-
ther evaluated the call rate per sample for specimens of HIV-1 CRF01_AE, subtype B,
CRF07_BC and CRF08_BC. For CRF01_AE, 90 out of 109 (82.6%) specimens had a call rate
greater than 90%, and 104 out of 109 (95.4%) specimens had a call rate greater than 80%. For
subtype B, 6 out of 12 (50%) specimens had a call rate greater than 90%, and 10 out of 12
(83.3%) specimens had a call rate greater than 80%. For CRF07_BC, 26 out of 26 (100%) speci-
mens had a call rate greater than 90% and the call rate of the 2 CRF08_BC specimens were
70%. Results were demonstrated in Fig 2II, 2III and 2IV respectively. The discrepancies of the
call rate per sample shown in Fig 2 were found to be mainly due to the genetic variations of
HIV-1 among specimens after sequence alignment. Other possible factors for the discrepancies
Fig 2. Summary of call rate per sample for the 159 clinical specimens A summary of call rate per sample for the total 159 clinical specimens and
specimens of HIV-1 CRF01_AE, subtype B, CRF07_BC and CRF08_BC are demonstrated. i) The total call rate per sample of all 159 clinical specimens; ii)
The call rate per sample of 109 specimens of CRF01_AE; iii) The call rate per sample of 12 specimens of subtype B and iv) The call rate per sample of 26
specimens of CRF07_BC and 2 specimens of CRF08_BC.
doi:10.1371/journal.pone.0153641.g002
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included the concentration of virus in the specimens and the quality of the PCR products.
Although the call rate per sample was not completely ideal, the assay was able to detect major
resistance mutations (M41L, K65R, M184V and G190A) in 150 out of 159 (94.3%) specimens
simultaneously.
Apart from the call rates, the reproducibility of the assay was evaluated. The reproducibility
of the platform was examined by amplifying the pol gene fragments from the same plasma speci-
mens of 12 patients. Interestingly, we found that all of the 10 alleles detected in these patients
were the same as those identified in the first time after excluded the failed detections (data not
shown). This result suggested the MS platform established was consistent and stable enough.
Estimation of the sensitivity for detecting drug resistant variants in mixed
viral populations
Since drug resistant HIV-1 may exist in very low frequency, it is necessary to understand the
sensitivity of this MALDI-TOFMS based assay for determining the presence of low abundance
mutant virus in mixed viral populations. To evaluate the sensitivity of this assay, a total of
100ng plasmid mixture was first prepared by mixing plasmids carrying wild type (WT) geno-
type (M184 in the RT region) and plasmids carrying mutant genotype (184V in the RT region)
in ratios as indicated in Fig 3. The mixtures were then subjected to nested PCR and analyzed
by the MALDI-TOF MS. Result in Fig 3 demonstrated the 184V mutant could be detected
when mutant to wild type ratio was as low as 2 to 8 (20%). This result was close to the clinical
and other conventional genotypic assays, which detected drug resistant variants at level about
20% of the circulating viral population [6,19].
Validation by DNA sequencing and Stanford University HIV drug
resistance database
To validate the MALDI-TOFMS result, the same PCR products of the 159 specimens used for
MALDI-TOFMS analysis were sequenced by conventional DNA sequencing. 154 out of 159
specimens were sequenced successfully and the sequences were submitted to Stanford University
HIV drug resistance database for generating the antiretroviral drug resistance profile of each
specimen. The drug resistance profiles generated from the sequences of drug resistant specimens
were concordant to the MALDI-TOFMS results except patient 12_46, after excluded the failed
detections. Indeed, the virus of this patient had a 184V mutation in the pol gene fragment when
the sequencing chromatogram was carefully analyzed (Fig 4B). A comparison of the MALDI-
TOFMS results and the drug resistance profiles of drug resistant specimens from the database is
shown in Table 3. Representative results demonstrating the concordance between the chromato-
grams of DNA sequencing and the MALDI-TOFMS results at two different drug resistance
mutation sites (M184V and K103N) are shown in Fig 4A.
In order to examine any discrepancies between the MALDI-TOFMS results and conven-
tional DNA sequencing results, results of the 154 specimens from both assays were compared.
In total 1540 alleles detected by both assays, 1446 (93.9%) were identical and 94 (6.1%) were
discordant. The discrepancies between the two assays were due to the failed detections by the
MALDI-TOF MS. Analysis of the DNA sequencing results revealed the MALDI-TOFMS
based assay missed these alleles mainly due to mismatches between the extension primers and
the viral sequences. The concordance rates between the results of the MALDI-TOF MS and the
DNA sequencing at each drug resistance mutation site in 154 patient specimens were summa-
rized in Table 4.
Conventional DNA sequencing method for identifying the presence of mixed viral geno-
types from patient specimens is time consuming and labor intensive. Although some computer
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programs can facilitate the sequence analysis, identification of low abundance variants by these
programs may be affected by the noise from the background of sequencing results. Alterna-
tively, the presence of low abundance variants may be missed if the sequencing results were
analyzed manually. As a result, there is a great demand for a rapid method for identifying
mixed viral populations in patients in order to allow doctors to arrange the treatment regimens
and to prevent the transmission of drug resistant strains. Interestingly, the assay used in this
study was able to detect mixed viral populations in two different patient specimens and the
results were concordant to the chromatogram obtained from DNA sequencing. One of the rep-
resentative results is shown in Fig 4B. Of these two specimens, no drug resistance mutation was
found in one sequence (data not shown) while the other one (patient 12_46), as shown in Fig
4B, no 184V mutation was identified after submitted both sequences to Stanford University
HIV drug resistance database for analysis. These results further validated the ability of this
MALDI-TOF MS based platform for the detection of mixed viral populations.
Fig 3. Evaluation of the sensitivity of the MALDI-TOF MS for detection of mixed genotypes. Results of MALDI-TOF MS and direct sequencing for the
PCR products obtained from different mixtures of the wild type plasmid (M184) and the mutant plasmid (184V) are demonstrated. The ratio of the plasmids in
the mixtures are as indicated. The 184V mutant could be detected when the ratio of mutant plasmid to wild type plasmid was as low as 2 to 8 in both
MALDI-TOF MS and direct sequencing. The site of mutation is indicated by a box in the sequencing chromatogram.
doi:10.1371/journal.pone.0153641.g003
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Discussion
The nationwide “Comprehensive AIDS Response Program” launched by Chinese government
provides free HAART for all AIDS patients living in rural areas and patients with financial dif-
ficulties living in urban districts [20,21]. Since the China’s National Free Antiretroviral Treat-
ment Program (NFATP) began in 2002, ART usage has scaled up rapidly. By the end of 2012,
more than 208,216 patients across the country had received free antiretroviral treatment [22].
Many studies found that the NFATP has successfully increased life expectancy and reduced
mortality among Chinese HIV patients [23–25]. Although rapid ART scale-up significantly
Fig 4. Comparison of the results between the MALDI-TOF MS and direct sequencing. Results of MALDI-TOF MS and direct sequencing for the PCR
products obtained from clinical specimens are demonstrated. a) i) A peak at molecular mass 6565.3 indicated a A (M184) to G (184V) mutation in codon 184
of the RT region. ii) A combined result of peaks at molecular mass 6736.5 (left) and 6423.3 (middle) indicated a AA (K103) to AC (N103) mutation in codon
103 of the RT region. The codon is indicated by a box in the sequencing chromatogram. b) The mixed genotypes at codon 184 and 190 detected by
MALDI-TOF MS as shown in the table were concordant to the sequencing chromatogram. The specific site of mixed genotype is indicated by a box.
doi:10.1371/journal.pone.0153641.g004
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reduced AIDS-related morbidity and mortality, HIV antiretroviral treatment programs are fac-
ing the challenge of potential widespread emergence and transmission of drug resistant HIV-1
[26–30]. As a result, it is necessary to establish a rapid drug resistance testing system in order
to assure the efficacy of the antiretroviral therapy.
In this study, we described the development and validation of a broadly reactive MALDI-
TOF MS based assay for multiplex detection of drug resistance mutations towards the com-
monly used NRTIs and NNRTIs for various HIV-1 strains, mainly CRF01_AE, CRF07_BC
and subtype B in China. Specifically, this assay could simultaneously detect mutations associ-
ated with drug resistance towards ABC, AZT, d4T, 3TC, ddI, TDF, NVP and EFV, which are
the reverse transcriptase inhibitors freely provided by the Chinese government and are used in
many developing countries in the world [31].
Table 3. Comparison of the HIV-DRmutations obtained fromMALDI-TOFMS and Stanford HIV-DR database.
Specimen
ID
Subtyping Mutations detected by MALDI-TOF MS Drug resistance proﬁle shown on the Stanford drug resistance
database
12_102 CRF01_AE M184V, G190A M184V, G190A
3_328 CRF01_AE M184V V75L, V106M, Y115F, V179D, M184V
28_139 CRF01_AE M184V, G190A M184V, G190A
8_42 CRF01_AE K65R K65R, V179D, Y181C
904 CRF01_AE M184V M184V
A654 CRF01_AE M184V, G190A V106M, M184V, G190A
676 CRF01_AE K101E/Q/P, G190A, Failed to call allele for
M184V
K101E, M184V, G190A
22_326 CRF01_AE K65R, K103N/S K65R, K103N, V106M
12_46 CRF01_AE M184V, G190A Y181C, M184I, G190A
25_13 B M184V, Failed to call both alleles for K103N/S V90I, K103N, M184V, K238N
9_636 B K103N/S K103N
10_774 B K65R K65R
478 CRF07_BC M184V M184V
16_559 CRF07_BC M184V D67G, K70E, V106M, Y115F, V179D, M184V, F227L
824 CRF08_BC K65R, M184V K65R, Y181C, M184V, G190C, H221Y
doi:10.1371/journal.pone.0153641.t003
Table 4. Concordance betweenMALDI-TOF MS and conventional DNA sequencing at each allele in 154 specimens.
Allele detected at each
site a
No. of allele detected by
MALDI-TOF MS
No. of failed detections by
MALDI-TOF MS
No. (%) of specimens with
concordant results
M41L [A/c/t]TG 150 4 150 (97.4)
K65R A[A/g]A 154 0 154 (100)
K101E/Q/P [A/g/c]AA 141 13 141 (91.6)
K101E/Q/P A[A/c]A 152 2 152 (98.7)
K103N/S A[A/g]A 140 14 140 (90.9)
K103N/S AA[A/G/t/c] 140 14 140 (90.9)
M184V [A/g]TG 151 3 151 (98.1)
G190A G[G/c]A 153 1 153 (99.4)
L210W T[T/g]G 125 29 125 (81.2)
T215F/Y [A/t]CC 140 14 140 (90.9)
Total 1446 94 1446 (93.9)
a Alleles to be detected are shown in the brackets and the small letters represent the mutant alleles
doi:10.1371/journal.pone.0153641.t004
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In comparison with recently reported multiplex genotypic HIV-1 drug resistance assays
[14,32], our assay showed broad reactivity in detecting drug resistance mutations for HIV-1
CRF01_AE, CRF07_BC and subtype B although fewer drug resistance mutations were investi-
gated. Our assay also worked for other HIV-1 strains such as URF_01/BC and CRF02_AG
(data not shown). Despite the relative low call rate per sample for the two CRF08_BC speci-
mens as shown in Fig 2IV, our assay was able to detect drug resistance mutations in one of the
CRF08_BC specimens as shown in Table 3. More specimens will be needed for evaluating the
efficiency of our assay for specimens of CRF08_BC in future. Indeed, the broad spectrum of
detection is of significant importance in areas consisting different HIV-1 strains and in clinics
where the genotypic information of the virus is always unavailable.
One of the greatest challenges for our assay is the genetic variation among different HIV-1
strains. As a result, we considered alleles with call rate per allele greater than 90% as an accept-
able detection rate. However, our data shown in Table 2 illustrated L210W, unlike other alleles,
had only a call rate per allele equal to 80.5%. Strictly, we will not accept the detection for this
allele as completely successful and thus a redesign of the extension primers for detecting
L210W will be required in future. In terms of the viral load required for our assay, we found
that 4 independent specimens with viral load less than 500 copies/ml reached a call rate per
sample higher than 90%. This result indicated the potential utility of this assay to detect muta-
tions at early phase of viral rebound.
Apart from the high concordance rate between this MALDI-TOF MS based assay and the
conventional sequencing, this assay was better than the conventional sequencing due to lower
concentration of PCR products was required per reaction as determined by a two-fold serial
dilutions approach (data not shown). In addition, this platform is capable of analyzing two
384-format chips (sufficient for total 126 samples plus two no template controls in each chip)
in a single run. Given the high-throughput nature of this assay, results of hundreds of samples
could be obtained within 36 hours including viral RNA extraction and nested PCR amplifica-
tion. Moreover, this assay greatly reduced the labor required as only three steps including neu-
tralization of unincoporated dNTPs, a PCR based iPLEX Gold reaction and desalting of
extension products were needed before data analysis.
Another advantage of this assay over conventional sequencing is that this system is auto-
mated and easy to be operated by following the user manual once the extension primers were
designed. Since genotyping results are readily available once the assay is finished, even individ-
uals with basic training in bioinformatics can interpret the results easily and in a time saving
manner.
Despite these advantages, both assays were estimated to have similar sensitivity for detecting
the variants in total viral population as mentioned. Although the cost per sample, including the
cost of viral RNA extraction and nested PCR amplification, for this MALDI-TOF MS based
assay (RMB 80.00 per sample) is considerably lower than that for commercially available geno-
typic assays, such as ViroSeq (RMB 1089 per sample) and TruGene (RMB 1344 per sample)
[8], a major limitation for implementing this assay in clinical settings and surveillance purpose
in China is that the cost per sample for in-house sequencing assay is cheaper. To a certain
extent, the higher cost has limited the number of mutations detected in our system. Fortu-
nately, once the cost reduced, more drug resistance mutations of biological significance can be
incorporated into the current assay by adding extension primers designed by designated com-
puter program.
Recent advances in next generation sequencing, such as ultra-deep sequencing have signifi-
cantly increased the sensitivity for detecting the low level drug resistant variants and permitted
the quantification of them. However, these assays are not suitable for routine surveillance in
developing countries such as China due to expensive cost and high technical content [33,34].
Detection of HIV-DRMutations in Reverse Transcriptase Gene Using SequenomMassARRAY1 System
PLOSONE | DOI:10.1371/journal.pone.0153641 April 19, 2016 12 / 15
Similar to other genotypic assays for detecting HIV-DR mutations, this assay can only ana-
lyze the known resistance mutations and fail to provide sequence data. Also, the sensitivity for
detecting low abundance variants is dependent on the number of viral templates provided for
cDNA synthesis and PCR amplification [35,36]. In addition to the above limitations, our assay
is a qualitative assay and cannot be used for the quantification of drug resistance mutations,
although the Sequenom massARRAY1 system is capable to quantify drug resistance muta-
tions in patient specimens.
Since HIV-1 with drug resistance mutations against different categories of antiretroviral
drugs has been identified, our future studies will be focusing on designing the multiplex assays
for detecting the drug resistance mutations against the protease inhibitors, integrase inhibitors
as well as entry inhibitors based on this Sequenom MassARRAY1 system. The feasibility to
establish a MALDI-TOF MS based assay, which can detect major HIV-DR mutations against
all categories of antiretroviral drugs will also be investigated in future.
Conclusions
Although the assay reported in this study was capable to detect drug resistance mutations for
HIV-1 CRF01_AE, CRF07_BC, subtype B and other strains, its practical application in clinics
was limited by the number of mutations detected at this moment. In conclusion, we provided a
proof of concept in which it is possible to establish a simple, rapid, broadly reactive and auto-
mated high-throughput platform for multiplex detection of major HIV-DR mutations towards
the commonly used NRTIs and NNRTIs in China using SequenomMassARRAY1 system.
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